FTHL17

Across TCGA pan-cancer cohorts, FTHL17 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FTHL17 data layer compared with 18 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FTHL17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FTHL17 expression acts as an unfavorable survival marker.

LUAD and ESCA are the cancer types where FTHL17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.223	0.677	.006	12	view →
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FTHL17–LUAD (OS)

Open the LUAD breakdown →